Antihypertensive treatment with calcium channel blockers and renal protection: focus on lercanidipine and lercanidipine/enalapril

N. Ferri, A. Corsini, R. Pontremoli

Department of Medicine, University of Padua, Padua, Italy. nicola.ferri@unipd.it

---

• Nephrology

OBJECTIVE: The aim of the study was to review the literature on clinical pharmacology of lercanidipine and experimental and clinical evidence and evaluate its ability to reduce proteinuria and preserve renal function when used as monotherapy or in combination with the angiotensin-converting enzyme (ACE) inhibitor enalapril.

MATERIALS AND METHODS: MEDLINE/PubMed was searched for appropriate keywords.

RESULTS: Lercanidipine, a third-generation calcium channel blocker, has been shown to have a unique pharmacological and clinical profile, which translates into favorable renal hemodynamic changes. The fixed-dose combination lercanidipine/enalapril has been proposed to overcome unmet therapeutic needs, often as the initial treatment in the high-risk patient.

CONCLUSIONS: Lercanidipine may be regarded as an ideal antihypertensive drug for patients at renal risk and possibly the preferred choice among calcium channel blocker drugs.

 

This article has been corrected on Nov 30, 2022. Erratum notice in: Eur Rev Med Pharmacol Sci 2022; 26 (22): 8204-8204.

Free PDF Download